Septerna (NASDAQ:SEPN) Releases Earnings Results, Misses Expectations By $0.15 EPS

Septerna (NASDAQ:SEPN) posted its quarterly earnings data on Monday. The company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.15), FiscalAI reports. The firm had revenue of $18.88 million during the quarter, compared to the consensus estimate of $20.78 million. Septerna had a negative return on equity of 15.43% and a negative net margin of 61.29%.

Septerna Price Performance

NASDAQ SEPN traded down $6.55 on Wednesday, hitting $45.79. 118,984 shares of the company were exchanged, compared to its average volume of 364,801. Septerna has a twelve month low of $18.64 and a twelve month high of $53.34. The firm has a market capitalization of $2.14 billion, a P/E ratio of -35.63 and a beta of 2.20. The company’s 50 day moving average price is $40.04 and its 200-day moving average price is $32.84.

Analyst Ratings Changes

A number of research analysts recently issued reports on SEPN shares. Stifel Nicolaus lifted their target price on Septerna from $49.00 to $60.00 and gave the stock a “buy” rating in a report on Tuesday. Guggenheim upped their price target on shares of Septerna from $51.00 to $65.00 and gave the company a “buy” rating in a report on Friday, November 6th. JonesTrading upped their price target on shares of Septerna from $43.00 to $62.00 and gave the company a “buy” rating in a report on Thursday, August 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Septerna in a research report on Thursday, October 15th. Finally, Wells Fargo & Company lifted their price objective on shares of Septerna from $50.00 to $61.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 4th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $56.44.

Insider Activity

In other news, SVP Daniel D. Long sold 3,333 shares of the business’s stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $37.83, for a total transaction of $126,087.39. Following the sale, the senior vice president owned 96,412 shares in the company, valued at $3,647,265.96. The trade was a 3.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Elizabeth Bhatt sold 4,000 shares of the company’s stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $37.41, for a total transaction of $149,640.00. Following the completion of the sale, the chief operating officer owned 174,209 shares of the company’s stock, valued at approximately $6,517,158.69. This trade represents a 2.24% decrease in their position. The SEC filing for this sale provides additional information. Company insiders own 5.80% of the company’s stock.

About Septerna

Septerna is a clinical-stage biotechnology company developing medicines that target G protein-coupled receptors (GPCRs), a large family of proteins involved in many biological processes. The company is based in South San Francisco, California. Its discovery platform is designed to identify drug candidates that act on GPCRs, including targets that have been difficult to address with conventional drug-development approaches. Septerna is advancing candidates for endocrine, metabolic and other disease areas, with an emphasis on small-molecule medicines.